Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome
2016-004395-22Phase 2Completed
- Sponsor
- Reata Pharmaceuticals
- Start
- Sep 2017
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of bardoxolone methyl in Alport syndrome, sponsored by Reata Pharmaceuticals. Started Sep 2017; status: completed.
02
Drugs
bardoxolone methyl
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on 2016-004395-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004395-22.